New Hope for Advanced MS Patients: Tolebrutinib Shows Promising Results in Clinical Trial

United States: A pharmaceutical under investigation has demonstrated its ability to help advanced multiple sclerosis (MS) patients postpone disorder-induced disability progression, according to a recent clinical study.

Breakthrough in Secondary Progressive MS Treatment

Science reports in the New England Journal of Medicine that tolebrutinib functioned to push back disability progression in patients with non-relapsing secondary progressive multiple sclerosis (SPMS) by 31%, as reported by HealthDay.

“This is the first clinical trial showing a positive effect in delaying disability progression in non-relapsing SPMS, a later form of the disease where neurological function gradually worsens over time and disability increases relentlessly,” lead researcher Dr. Robert Fox said in a news release. He’s a neurologist at the Cleveland Clinic’s Mellen Center for MS Research and Treatment.

The U.S. FDA conducts a review process for Tolebrutinib at present. Spastic MS patients lack any FDA-approved medical therapies, according to research background statements.

Large-Scale Study Shows Encouraging Results

A clinical trial conducted for MS patients was done at 264 sites in 31 countries to enroll patients between 18 and 60 years of age who exceeded 1,100 individuals. The clinical trial involved assigning patients by random selection into two groups: one group received daily oral medications of tolebrutinib and another group took daily oral placebo tablets.

An experimental drug has been found to help patients with advanced multiple sclerosis delay the progressive course of the disease.https://t.co/Vtsv2wk9MY
— Ian Weissman, DO (@DrIanWeissman) April 10, 2025

Mechanism and Origins of Tolebrutinib

Tolebrutinib functions as a tyrosine kinease inhibitor which medical researchers initially created for lymphoma and blood illness treatment. Prior to cancer proliferation, these drugs impede enzymes that are responsible for controlling cell multiplication.

The percentage of patients administered tolebrutinib who experienced disability progression from MS amounted to 23% after six months while the placebo group reached 31%. Patients receiving the experimental drug showed decreased disability symptoms by 31% based on statistical analysis data.

Results indicate that tolebrutinib also showed additional beneficial effects.

The drug therapy group observed enhanced disability relief at a rate twice as high as the patients on placebo medication, with 8.6% compared to 4.5%.

A distinct research finding demonstrated that patients administered Tolebrutinib showed a 20% improvement in their timed 25-foot walk capacity during the three-month trial period.

Research showed lower numbers of brain and spinal cord lesions associated with MS emerged less frequently in drug-treated participants as opposed to participants taking a placebo.

Safety Concerns: Liver Monitoring Required

"In participants with nonrelapsing secondary progressive #MultipleSclerosis, the risk of disability progression was lower among those who received treatment with #tolebrutinib than among those who received placebo." https://t.co/7olclAo8Ur pic.twitter.com/LKhbNO0DhJ
— IJMSC (@IJMSCtweets) April 9, 2025

Studies revealed that tolebrutinib elevates the chance of liver damage among patients. Clinical laboratory assessments showed elevated enzyme levels of injury in 4% of tolebrutinib participants when compared to 1.6% of patients receiving placebo.

“If approved, the drug will likely require intensive monitoring of liver function enzymes during the first three months of therapy, with less frequent monitoring thereafter,” Fox said.

“It appears that about 1 in 200 patients will have severe elevation of liver enzymes during the first three months of use, so careful monitoring is important, and the drug should be stopped immediately in those with liver enzyme elevations,” he added.

According to Fox, tolebrutinib seems to function by reducting inflammation in the brain and spinal cord, as reported by HealthDay.

“The drug offers the potential for a new class of medications for the treatment of MS, the leading cause of non-traumatic disability in young adults,” Fox said.

Sanofi, the company that developed tolebrutinib, financed the clinical trial.